Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAMM: Dabrafenib, Trametinib, and Hydroxychloroquine in BRAF-mutant Melanoma
NCT02257424Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine in melanoma, sponsored by Abramson Cancer Center. Started Oct 2014; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02257424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257424.